GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Change In Inventory

Halberd (Halberd) Change In Inventory : $0.00 Mil (TTM As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Change In Inventory?

Halberd's change in inventory for the quarter that ended in Jul. 2023 was $0.00 Mil. It means Halberd's inventory stayed the same from Jul. 2022 to Jul. 2023 .

Halberd's change in inventory for the fiscal year that ended in Jul. 2023 was $0.00 Mil. It means Halberd's inventory stayed the same from Jul. 2022 to Jul. 2023 .

Halberd's Total Inventories for the quarter that ended in Jul. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Halberd's Days Inventory for the quarter that ended in Jul. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Halberd's Inventory-to-Revenue for the quarter that ended in Jul. 2023 was 0.00.


Halberd Change In Inventory Historical Data

The historical data trend for Halberd's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Change In Inventory Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Change In Inventory
- - -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Change In Inventory - - -

Halberd Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Inventory for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd  (OTCPK:HALB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Halberd's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0.002*365 / 2
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Halberd's Inventory Turnover for the quarter that ended in Jul. 2023 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Halberd's Inventory to Revenue for the quarter that ended in Jul. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd Change In Inventory Related Terms

Thank you for viewing the detailed overview of Halberd's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236